Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03091517
Other study ID # GlycoLeap
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 22, 2017
Est. completion date May 28, 2018

Study information

Verified date July 2018
Source Duke-NUS Graduate Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This single arm pilot study will explore the feasibility of GlycoLeap, a proprietary online lifestyle modification and self-management education program developed in Singapore for people with type 2 diabetes, as an add-on to primary care delivered through one of the SingHealth Polyclinics.


Description:

Lifestyle modification - focusing on a healthy diet, regular exercise and behaviour change - are the mainstay of first-line therapies in managing diabetes. There is strong evidence that lifestyle interventions can result in modest weight loss and improvements in clinical metrics such as glycated haemoglobin (HbA1c), blood pressure and cholesterol. For people with type 2 diabetes, lifestyle modification and self-management education can lead to improved clinical outcomes and reduced risks of complications.

Operationally, such interventions are often difficult to administer in the primary care and community setting because of lack of provider time/resources/training and difficulty in engaging patients. Fortunately, there is a growing body of evidence which shows that online programs and smartphone-based interventions can lead to improved clinical outcomes like weight loss and HbA1c reduction. Moreover, these interventions can be disseminated to a larger group of people and at a low cost. However, results from community based studies often fail to live up to what is achieved in clinical trials due to lack of clinician oversight and support. Without this support, patients often fail to engage in the intervention to the levels required for health benefits to materialize.

This feasibility study will explore the use of GlycoLeap, a proprietary online lifestyle modification and self-management education program developed in Singapore for people with type 2 diabetes, as an add-on to primary care delivered through one of the SingHealth Polyclinics. The goal of the study is to test whether patients with diabetes who receive care at the clinic are amenable to such an intervention, to quantify program fidelity for those who do enroll in the study, and to explore the extent to which the intervention can be used in conjunction with primary care in efforts to improve health outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date May 28, 2018
Est. primary completion date May 19, 2018
Accepts healthy volunteers No
Gender All
Age group 21 Years to 70 Years
Eligibility Inclusion Criteria:

1. Age 21 - 70 years

2. Medical diagnosis of Type 2 diabetes in electronic health records or based on World Health Organisation diagnostic criteria

3. Last HbA1c result within 2 months of = 7.5%

4. BMI > 23 kg/m2 (if Asian) or BMI > 25 kg/m2 (if non-Asian)

5. Not on insulin

6. Owns a smartphone (iPhone or Android phone) and able to use it

Exclusion Criteria:

1. Last HbA1c blood test older than 2 months

2. Cancer requiring treatment in past 5 years

3. Cardiovascular disease (heart attack or cardiac procedure within past 3 months)

4. Stroke or history/treatment for transient ischemic attacks in past 3 months

5. Chronic renal failure or dialysis

6. Amputation of lower limbs

7. Current use of medication for weight loss

8. Chronic treatment with systemic corticosteroids

9. History of bariatric surgery or extensive bowel resection

10. Unable to understand English

Study Design


Intervention

Behavioral:
GlycoLeap
GlycoLeap is a 24-week programme includes the following features: Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete. The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback.

Locations

Country Name City State
Singapore SingHealth Polyclinics - Tampines Singapore

Sponsors (2)

Lead Sponsor Collaborator
Duke-NUS Graduate Medical School SingHealth Polyclinics

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in HbA1c levels (Effectiveness) HbA1c or glycated haemoglobin is a measure of blood glucose levels. We will assess change in HbA1c levels. Baseline, Month 6
Secondary Change in weight (Effectiveness) We will assess change in weight Baseline, Month 6
Secondary Proportion of individuals who are willing to participate (Reach) Percentage of participants offered the GlycoLeap programme who agree to enrol Baseline
Secondary Extent of engagement in completing online health lessons (Implementation) Number of online GlycoLeap health lessons completed Throughout 6 month intervention duration
Secondary Extent of engagement in submitting blood glucose logs (Implementation) Number of blood glucose measurements logged per week in GlycoLeap's smartphone app Throughout 6 month intervention duration
Secondary Extent of engagement in submitting weight logs (Implementation) Number of weight measurements logged per week in GlycoLeap's smartphone app Throughout 6 month intervention duration
Secondary Extent of engagement in submitting meal logs (Implementation) Number of meals logged per week in GlycoLeap's smartphone app Throughout 6 month intervention duration
Secondary Extent of engagement with health coach (Implementation) Number of messages sent to health coaches per week through GlycoLeap's smartphone app Throughout 6 month intervention duration
Secondary Change in HbA1c (primary outcome) as a function of program engagement (Effectiveness) We will test whether those with greater engagement with the GlycoLeap program show greater improvements in HbA1c (primary outcome). Baseline, Month 6, Throughout 6 month intervention duration
Secondary Change in weight loss (secondary outcome) as a function of program engagement (Effectiveness) We will test whether those with greater engagement with the GlycoLeap program show greater improvements in weight loss (secondary outcome). Baseline, Month 6, Throughout 6 month intervention duration
Secondary Degree of user satisfaction with the GlycoLeap program (Maintenance) We will conduct a preliminary assessment of maintenance at the individual level via a user satisfaction survey at the month 6 follow-up. Participants will rate the smartphone app on a scale of 1 (Poor) to 5 (Excellent) and whether they would recommend the app to others for managing their diabetes on a scale of 1 (Would not recommend) to 5 (Would highly recommend). Month 6
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance